BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 8418769)

  • 1. Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.
    Becker RC
    Arch Pathol Lab Med; 1993 Jan; 117(1):89-96. PubMed ID: 8418769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platelet activation in acute coronary syndrome and interventional therapy].
    Bigalke B; Lindemann S; Gawaz M
    Hamostaseologie; 2007 Dec; 27(5):338-43. PubMed ID: 18060243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
    Chesebro JH; Webster MW; Zoldhelyi P; Roche PC; Badimon L; Badimon JJ
    Circulation; 1992 Dec; 86(6 Suppl):III100-10. PubMed ID: 1424043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes.
    Puma JA; Sketch MH
    J Am Osteopath Assoc; 2000 Nov; 100(11 Suppl):S8-12. PubMed ID: 11191119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cardiovascular events after acute coronary syndrome.
    Wallentin L
    Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy for ischemic heart disease in the elderly.
    Frishman WH; Miller KP
    Geriatrics; 1988 Dec; 43 Suppl():46-56. PubMed ID: 3056785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet aggregation and antiplatelet agents in acute coronary syndromes].
    Collet JP; Choussat R; Montalescot G
    Med Sci (Paris); 2004 Mar; 20(3):291-7. PubMed ID: 15067573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of antiplatelet agents in the treatment of ischemic cardiopathy].
    Bonhorst D
    Rev Port Cardiol; 1989 Apr; 8(4):261-4. PubMed ID: 2534356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of platelets and platelet inhibition in acute myocardial infarction.
    Valettas N; Herrmann HC
    Coron Artery Dis; 2003 Aug; 14(5):357-63. PubMed ID: 12878900
    [No Abstract]   [Full Text] [Related]  

  • 10. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis.
    Kamat SG; Schafer AI
    Coron Artery Dis; 1995 Dec; 6(12):930-5. PubMed ID: 8723014
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the platelet.
    Futterman LG; Lemberg L
    Am J Crit Care; 1997 Sep; 6(5):406-14. PubMed ID: 9283679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
    Rajagopal V; Bhatt DL
    Semin Thromb Hemost; 2004 Dec; 30(6):649-55. PubMed ID: 15630671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis.
    Eccleston D; Topol EJ
    Coron Artery Dis; 1995 Dec; 6(12):947-55. PubMed ID: 8723017
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet drugs.
    De Meyer SF; Vanhoorelbeke K; Broos K; Salles II; Deckmyn H
    Br J Haematol; 2008 Aug; 142(4):515-28. PubMed ID: 18513285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute myocardial infarction: thrombolysis].
    Branzi A; Ortolani P
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):711-5. PubMed ID: 12497809
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of platelets in the pathophysiology of acute coronary syndrome.
    Massberg S; Schulz C; Gawaz M
    Semin Vasc Med; 2003 May; 3(2):147-62. PubMed ID: 15199478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.